Afamelanotide

Definition

Afamelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone and an agonist at the melanocortin 1 receptor; the label describes the active ingredient as a synthetic peptide containing 13 amino acids and prints its sequence ^[1].

Its receptor is the one that governs pigmentation, which separates it from the rest of its class here. PT-141 and setmelanotide act at melanocortin 4, and Melanotan II is a non-selective analogue with no lawful route at all.

The pre-approval literature calls this compound melanotan-I, and two of the human reports in its trial record still carry that name ^[2]. A reader who arrives from the tanning market is therefore one letter away from a different molecule with a different legal position, and the approval described below belongs to a product rather than to a name.

Evidence

Across five name variants PubMed returns 269 indexed records, of which 142 carry the Humans subject heading, 13 the clinical-trial publication type and 5 the randomized-controlled-trial type ^[2]. All thirteen were opened and read; twelve name a variant and one does not ^[2].

Only two of the twelve concern the approved use. The registrational evidence is a pair of multicenter randomized placebo-controlled trials of the 16 mg implant, 74 patients in the European Union and 94 in the United States, whose primary endpoint was hours of direct exposure to sunlight without pain ^[3].

The result is measured in hours of daylight rather than in a disease resolved. Median pain-free time after six months was 69.4 hours against 40.8 hours on placebo in the United States trial; the European Union trial, which ran to nine months on five implants rather than three, reported 6.0 hours against 0.8 hours ^[3].

The remaining ten trial-type records are other dermatology and one neurology study, and none of them supports the label. A randomized multicenter trial paired the implant with narrowband ultraviolet B phototherapy in vitiligo ^[4], and the oldest records are pigmentation pharmacology rather than treatment of anything ^[5].

Side effects

The Scenesse label draws its safety data from three randomized, vehicle-controlled trials in 244 adults with erythropoietic protoporphyria, 125 of whom received the implant ^[8]. The most common adverse reactions were implant site reactions, in 21 percent against 10 percent on vehicle, most often discoloration at the implant site; nausea, in 19 percent against 14 percent; and oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, new or changed moles and respiratory tract infection, each in 4 to 7 percent ^[8].

Pigment change is an expected effect rather than a rare one. The label warns that afamelanotide may darken the skin generally and darken existing moles and freckles because of how it works, and it recommends a full body skin examination twice a year to monitor existing and new pigmented lesions ^[8].

Serious hypersensitivity reactions, including anaphylaxis, hives and angioedema, have been reported since approval. The label contraindicates the implant for anyone with a history of severe hypersensitivity to afamelanotide or to any ingredient in the product, and states that a patient who has such a reaction should not receive it again ^[8].

Some groups have little or no data behind them. Safety and effectiveness have not been established in children, there are no data on use in pregnancy, and the trials enrolled too few people aged 65 and over to show whether they respond differently ^[8].

Educational summary of the cited sources, not medical advice; a prescriber weighs these risks against a person’s own history.

Lawful access

The lawful supply route is the approved product. FDA approved afamelanotide implant under new drug application 210797 on October 8, 2019 as a Type 1 new molecular entity, and Drugs@FDA records Scenesse as a 16 mg subcutaneous implant marketed as prescription-only, with one labeling supplement approved August 12, 2024 ^[6].

The label names one population and stops. In the version effective May 11, 2026 the product is indicated "to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria", and no other use appears in it ^[1].

Compounding does not arise for this molecule. Afamelanotide appears in none of the three categories of the section 503A bulks list published May 14, 2026 ^[7], which is the ordinary position of a substance whose marketed product supplies it.

Related molecules

Afamelanotide is filed with the melanocortins beside PT-141, setmelanotide and Melanotan II. Three of the four hold approvals and every one of those approvals names a population rather than a market: a photodermatosis, one form of low sexual desire in premenopausal women, and a set of rare genetic and acquired obesities. The fourth member, the one with the widest gray market, has no lawful route.

The approved peptide drugs table places this product beside the rest of the approved set, and the human trial record carries the census behind the counts above. What removal does not mean covers the position of the compound this one is most often confused with.

Melanotan I vs II separates this approved product from the unapproved compound one letter away, measure by measure.

Elsewhere in this index